Swiss pharma Roche’s Tecentriq (atezolizumab) became the first PD-L1 inhibitor to be approved by US Food and Drug Administration (FDA). …
You have read of your 8 free articles this month.
Subscribe to
Medgenera All-Access
Enjoy unlimited access to all contents, resources, exclusive market research reports, databases, surveys and many more features by subscribing to Medgenera All-Access.
Access articles & resources worth up to US $4, 000 per month.
Authentic, Ad-free Reporting
High-quality, Exclusive Content
Original Market Research Reports
Original Resources & Databases
Global Surveys & Guidelines
Lowest Subscription Pricing
Healthcare News You Won't Read Elsewhere
Most up-to-date information, original and in-depth reviews, full-length exclusive market reports and forecasts, full-access to the smart knowledge base centres, useful resources and databases.
Access articles & resources worth up to $4000.
More in New Drug Approvals
New Drug Approvals
8 Facts about the Second FDA-Approved Gene Therapy for Cancer
Cancer is a gloomy word. When a person comes to know about his cancer for the first time, all his ...
New Drug Approvals
Breakthrough Lens Technology Helps Cataract Patients Go Glass Free
With increasing age, many people face various eye-related disorders. One of the most common conditions among them is the cataract. ...
New Drug Approvals
FDA Approves First Two-Drug Therapy for HIV Treatment
The US FDA approved GlaxoSmithKline’s (GSK) Juluca® as the first complete regimen containing only two drugs for the treatment of ...
New Drug Approvals
First Three-in-One Inhaler Therapy for Lung Disease, COPD Reaches Europe
UPDATE: GlaxoSmithKline/Innoviva‘s single inhaler, three-in-one therapy- Trelegy Ellipta received marketing approval in the European Union for the treatment of adult patients ...
Most Popular
GROW
7 New Ideas to Start a Healthcare Business in India (2018)
Highlights Herein, we are proposing the seven new healthcare business ideas in India in 2018 which are based on our ...
NEWLY PUBLISHED
Pharma Patents: Can India Reward Incremental Innovation?
Leave a reply